New drug could cut repeat eye surgeries in diabetics

NCT ID NCT06191094

ENROLLING_BY_INVITATION Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug farcimab (Vabysmo), given as an injection before and after eye surgery, can reduce bleeding complications in people with diabetes who have bleeding inside the eye. About 100 adults will receive either farcimab or a sham injection. The goal is to see if farcimab lowers the chance of needing another surgery and helps improve vision.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: farcimab (Vabysmo) injection
What this could lead to: If it works, this could reduce the need for repeat surgeries and improve vision recovery in diabetic patients with eye bleeding.
What could go wrong: This is a small, early-phase trial with only 100 participants. The drug may not reduce bleeding better than sham, and there are risks from the injection itself, such as infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic retinopathy proliferative diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC RETINOPATHY VITREOUS HEMORRHAGE DUE TO DIABETES MELLITUS

Contacts and locations

Locations

Sue Anschutz-Rodgers Eye Center

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.